Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Mexico and Argentina for Breast Cancer, NSCLC, CRC and Malignant Melanoma | Physician & Payer Forum | Mexico and Argentina | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
Biomarker-Driven Prescribing in Oncology: Physician and Payer Insights on Evolving Trends in Key Indications | Physician & Payer Forum | US | 2014
Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as…
Getting to Market Quicker: U.S. Physician and Payer Perceptions of Breakthrough Designation for Malignant Melanoma, Breast Cancer, NSCLC, Chronic Lymphocytic Leukemia, and Multiple Myeloma | Physician & Payer Forum | US | 2014
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Breast Cancer (The Expanding Role of Targeted Agents in Breast Cancer: Physician and Payer Receptivity to the Integration of Novel Premium-Priced Therapies in Highly Generic Market Segments) | Physician & Payer Forum | US | 2014
Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…
